51304-61-1

Basic information

• Product Name: 4-(4-CHLOROPHENYL)-1,2,3,6-TETRAHYDROPYRIDINE HYDROCHLORIDE
• Synonyms: TIMTEC-BB SBB003282;4-(4-CHLOROPHENYL)-1,2,3,6-TETRAHYDROPYRIDINE HYDROCHLORIDE;4-(4-CHLOROPHENYL)-1,2,3,6-TETRAHYDROPYRIDINE MONOHYDROCHLORIDE;4-(4-Chlorophenyl)-1,2,3,6-tetrahydro-pyridine HCl;4-(4-chlorophenyl)-1,2,3,6-tetrahydropyridinium chloride;4-(4-Chlorophenyl)-1,2,3-tetrahydropyridinehydrochloride;4-(4-CHLOROPHENYL)-1,2,3,6-TETRALPHA-HYDROPYRIDINE HYDROCHLORIDE 97%;4-(4-Chlorophenyl)-1,2,3,6-tetrahydropyridinehydrochloride,97%
• CAS NO: 51304-61-1
• Molecular Formula: C₁₁H₁₂ClN*ClH
• Molecular Weight: 230.13
• EINECS: 257-126-6
• Product Categories: C9 to C46Heterocyclic Building Blocks;Halogenated Heterocycles;Heterocyclic Building Blocks;Pyridines
• Mol File: 51304-61-1.mol
• Article Data: 2

Chemical Properties

• Melting Point: 199-204 °C(lit.)
• Boiling Point: 296.5 °C at 760 mmHg
• Flash Point: 133.1 °C
• Appearance: White to light yellow/Crystalline Powder
• Density: g/cm³
• Vapor Pressure: 0.00143mmHg at 25°C
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• Sensitive: Hygroscopic
• CAS DataBase Reference: 4-(4-CHLOROPHENYL)-1,2,3,6-TETRAHYDROPYRIDINE HYDROCHLORIDE(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(4-CHLOROPHENYL)-1,2,3,6-TETRAHYDROPYRIDINE HYDROCHLORIDE(51304-61-1)
• EPA Substance Registry System: 4-(4-CHLOROPHENYL)-1,2,3,6-TETRAHYDROPYRIDINE HYDROCHLORIDE(51304-61-1)

Safety Data

• Hazard Codes: T,Xi
• Statements: 23/24/25-40-36/37/38
• Safety Statements: 26-27-36/37/39-45-36
• RIDADR: UN 2811 6.1/PG 2
• WGK Germany: 3
• HazardClass: 6.1(b)
• PackingGroup: III
• Hazardous Substances Data: 51304-61-1(Hazardous Substances Data)

Usage

Description

4-(4-CHLOROPHENYL)-1,2,3,6-TETRAHYDROPYRIDINE HYDROCHLORIDE is a white to light yellow crystalline powder that serves as a crucial reagent in the synthesis of various compounds, particularly in the pharmaceutical industry. Its chemical structure allows it to be used in the development of small molecule inhibitors and agonists, making it a valuable component in drug discovery and design.

Uses

Used in Pharmaceutical Industry:
4-(4-CHLOROPHENYL)-1,2,3,6-TETRAHYDROPYRIDINE HYDROCHLORIDE is used as a reagent for the synthesis of small molecule inhibitors targeting menin-MLL interaction in leukemia. This application is significant as it aids in the development of potential treatments for leukemia, a type of cancer that affects the blood and bone marrow.
Additionally, 4-(4-CHLOROPHENYL)-1,2,3,6-TETRAHYDROPYRIDINE HYDROCHLORIDE is used in the preparation of 5-HT2C agonists. These agonists are important in the development of medications for various conditions, including psychiatric disorders and other central nervous system-related diseases. The use of this reagent in the synthesis of 5-HT2C agonists highlights its versatility and importance in the pharmaceutical industry.

InChI:InChI=1/C11H12ClN/c12-11-3-1-9(2-4-11)10-5-7-13-8-6-10/h1-5,13H,6-8H2/p+1

Upstream product

• 56108-25-9 N-benzyl-4-(4-chlorophenyl)-4-hydroxypiperidin 
• 235109-63-4 4-(4-chloro-phenyl)-4-hydroxy-piperidine-1-carboxylic acid tert-butyl ester 
• 106-39-8 bromochlorobenzene 
• 3612-20-2 1-phenylmethyl-4-piperidone 
• 79099-07-3 N-tert-butyloxycarbonylpiperidin-4-one 
• 138647-49-1 4-Trifluoromethanesulfonyloxy-3,6-dihydro-2H-pyridine-1-carboxylic acid tert-butyl ester 
• 138647-50-4 4-(4-Chloro-phenyl)-3,6-dihydro-2H-pyridine-1-carboxylic acid tert-butyl ester 

Downstream Products

• 1026047-44-8 1-[4-(4-Chloro-phenyl)-3,6-dihydro-2H-pyridin-1-yl]-4-(1H-indol-3-yl)-butan-1-one 
• 120446-99-3 (+/-)-trans-2-<4-(p-chlorophenyl)-1,2,3,6-tetrahydropyridino>cyclohexanol 
• 152565-99-6 4-(4-chlorophenyl)-1-(3-oxo-3-phenylpropyl)-1,2,5,6-tetra-hydropyridine 
• 160857-20-5 4-(4-chorophenyl)-1-(cyanocyclohexyl)-1,2,3,6-tetrahydropyridine 

Relevant articles and documents

Identification of novel small-molecule inhibitors targeting menin-MLL interaction, repurposing the antidiarrheal loperamide

Leukemia with a mixed lineage leukemia (MLL) rearrangement, which harbors a variety of MLL fusion proteins, has a poor prognosis despite the latest improved treatment options. Menin has been reported to be a required cofactor for the leukemogenic activity of MLL fusion proteins. Thus, the disruption of the protein-protein interactions between menin and MLL represents a very promising strategy for curing MLL leukemia. Making use of menin-MLL inhibitors with a shape-based scaffold hopping approach, we have discovered that the antidiarrheal loperamide displays previously unreported mild inhibition for the menin-MLL interaction (IC50 = 69 ± 3 μM). In an effort to repurpose this drug, a series of chemical modification analyses was performed, and three of the loperamide-based analogues, DC-YM21, DC-YM25 and DC-YM26 displayed better activities with IC50 values of 0.83 ± 0.13 μM, 0.69 ± 0.07 μM and 0.66 ± 0.05 μM, respectively. Further treatment with DC-YM21 demonstrated potent and selective blockage of proliferation and induction of both cell cycle arrest and differentiation of leukemia cells harboring MLL translocations, which confirmed the specific mechanism of action. In conclusion, molecules of a novel scaffold targeting menin-MLL interactions were reported and they may serve as new potential therapeutic agents for MLL leukemia.